<div id="readability-page-1"><p>04:30 PM EDT, 04/30/2026 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:</p><p>We raise our target price to $42 from $36, 13.6x our 2027 EPS forecast of $3.09, aboveTEVA's historical forward P/E average, justified in our view, by its improving growth prospects. We lower our 2026 EPS estimate to $2.11 from $2.77 to adjust for the Emalex acquisition impact. We keep our 2027 EPS estimate at $3.09. Teva reported a solid Q1, beating expectations, driven by the continued strong performance of its innovative growth engines (AUSTEDO, AJOVY, and UZEDY) which collectively grew 41% and are successfully offsetting the anticipated revenue decline from the loss of exclusivity for the generic REVLIMID. The newly announced $700M Emalex acquisition, expected to close in Q3, is a significant strategic move, and a major positive, in our view. The deal will bring the NDA-ready, first-in-class lead asset Ecopipam to treat Tourette syndrome, which has a significant unmet need, into Teva's neuroscience pipeline.  We think the acquisition can accelerate TEVA's shift toward innovative, high-margin products.</p> <p>MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</p></div>

梯瓦制藥

<p>CFRA 已將梯瓦製藥的評級從持有上調至買入，將目標價格從 36 美元提高至 42 美元。分析師將 2026 年的每股收益預期下調至 2.11 美元，原因是 Emalex 收購的影響，但維持 2027 年的每股收益預期為 3.09 美元。梯瓦第一季度的業績超出預期，主要得益於創新產品的強勁增長。預計在第三季度完成的 7 億美元 Emalex 收購被視為一項戰略舉措，旨在通過新治療方案增強梯瓦的神經科學產品線，以應對抽動症</p>

研究警報：CFRA 將梯瓦製藥的股票評級從持有上調至買入